載入...
Hypokalemic Paralysis Secondary to Immune Checkpoint Inhibitor Therapy
Introduction of immune checkpoint inhibitors (ICIs) has led to significant improvements in the treatment of multiple malignancies. Anti-programmed cell death protein 1 (PD-1) and anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) are two essential ICIs that have been FDA approved since 2011. As the use...
Na minha lista:
| 發表在: | Case Rep Oncol Med |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Hindawi
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5698791/ https://ncbi.nlm.nih.gov/pubmed/29250451 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2017/5063405 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|